| Valuation method | Value, ¥ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
tella, Inc. (2191.T) is a Tokyo-based biotechnology company specializing in regenerative and cell medicine research and development. Founded in 2004, tella focuses on dendritic cell vaccine therapy for cancer treatment, providing affiliated medical institutions with cutting-edge techniques and operational expertise. The company also offers consultation services for establishing and maintaining cell processing centers, along with training for cell cultivation technicians. Additionally, tella supports therapy assessment, regulatory documentation, and physician-patient education. Operating in Japan's growing biotechnology sector, tella plays a critical role in advancing cell-based therapies, positioning itself as a niche player in the healthcare industry. Despite its specialized focus, the company faces challenges in scaling its operations and achieving profitability in a highly competitive and capital-intensive field.
tella, Inc. presents a high-risk, high-reward investment opportunity due to its focus on innovative dendritic cell vaccine therapies for cancer. The company operates in a promising but capital-intensive segment of biotechnology, evidenced by its negative net income (-¥948.8M) and operating cash flow (-¥813.6M) in FY 2021. While its revenue (¥106.4M) is modest, tella's beta of 1.85 indicates significant volatility, aligning with the speculative nature of biotech investments. The company's niche expertise in cell therapy and regenerative medicine offers long-term potential, but investors should be cautious about its financial sustainability and ability to scale in a competitive market. The dividend yield (¥1.4 per share) provides minimal compensation for the inherent risks.
tella, Inc. competes in the specialized field of dendritic cell vaccine therapy, a subset of the broader immuno-oncology and regenerative medicine markets. Its competitive advantage lies in its deep operational know-how and consultation services for cell processing centers, which differentiate it from larger biotech firms focused on mass-market drug development. However, tella's small scale (¥106.4M revenue) and negative profitability limit its ability to invest in R&D at the same level as global biotech leaders. The company's reliance on affiliated medical institutions in Japan also restricts its geographic diversification. While tella's expertise in dendritic cell therapy is valuable, it faces intense competition from firms with stronger financial backing and broader pipelines. Its ability to form strategic partnerships or secure additional funding will be critical to maintaining relevance in the rapidly evolving cell therapy space.